Cancer Stem Cells
Cancer stem cells (CSCs) are populations of cancer cells that have the properties of stem cells i.e. self-renewal and ability to generate differentiated progenies. CSCs have high plasticity, which changes their phenotypic and functional appearance. They have important roles in tumor development, expansion, resistance, relapse and metastasis. Multiple studies have shown that CSCs originate from non-malignant stem or progenitor cells. Inhibition of developmental signaling pathways that are critical for stem and progenitor cell homeostasis and function has important implications in strategies to target CSCs in cancer research.
Studies have shown that CSCs develop several mechanisms to protect themselves from toxins and genotoxic stress, including enhanced DNA damage repair capacity, increased expression of drug transporters, maintenance of a low reactive oxygen species (ROS) environment, and recruitment of a protective niche. Therefore, targeting signaling pathways that are required to maintain stem cells is the current therapeutic strategy for CSCs. For example, hedgehog pathway, Notch and Wnt signaling pathways.
Newly developed drugs targeting surface markers of CSCs opens the new avenues for cancer therapy, such as CD44, CD133, EpCAM, Sox2, and Oct-3/4.
-
Momelotinib mesylate
0 ImagesCat. No.: HY-10963CAS No.: 1056636-07-7Synonyms: CYT387 mesylateMomelotinib mesylate (CYT387 mesylate) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.
-
IM-12 (Standard)
0 ImagesCat. No.: HY-12292RCAS No.: 1129669-05-1
-
DTP3 (Standard)
0 ImagesCat. No.: HY-100538RCAS No.: 1809784-29-9
-
TBCA (Standard)
0 ImagesCat. No.: HY-110052RCAS No.: 934358-00-6TBCA (Standard) is the analytical standard of TBCA (HY-110052). This product is intended for research and analytical applications. TBCA is a highly selective CK2 (casein Kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other Kinases.
-
Tagtociclib hydrate (Standard)
0 ImagesCat. No.: HY-137894ARCAS No.: 2733575-91-0Synonyms: PF-07104091 hydrate (Standard)Tagtociclib hydrate (Standard) is the analytical standard of Tagtociclib hydrate (HY-137894A). This product is intended for research and analytical applications. PF-07104091 hydrate is a potent and selective CDK2/cyclin E1 and GSK3β inhibitor, with Kis of 1.16 and 537.81 nM, respectively. PF-07104091 hydrate has anti-tumor activity for cyclin E1-amplified cancers. (patent WO2020157652A2).
-
Y-33075 dihydrochloride (Standard)
0 ImagesCat. No.: HY-10069RCAS No.: 173897-44-4Y-33075 (dihydrochloride) (Standard) is the analytical standard of Y-33075 (dihydrochloride) (HY-10069). This product is intended for research and analytical applications. Y-33075 dihydrochloride is a selective ROCK inhibitor with an IC50 of 3.6 nM.
-
RO4929097 (Standard)
0 ImagesCat. No.: HY-11102RCAS No.: 847925-91-1Synonyms: RG-4733 (Standard)RO4929097 (Standard) is the analytical standard of RO4929097 (HY-11102). This product is intended for research and analytical applications. RO4929097 (RG-4733) is an orally active γ secretase inhibitor with an IC50 of 4 nM, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively.
-
NSC23005 sodium (Standard)
0 ImagesCat. No.: HY-100791RCAS No.: 1796596-46-7NSC23005 (sodium) (Standard) is the analytical standard of NSC23005 (sodium) (HY-100791). This product is intended for research and analytical applications. NSC23005 sodium is a novel and effective p18 inhibitor (ED50=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.
-
MK-8353 (Standard)
0 ImagesCat. No.: HY-111407RCAS No.: 1184173-73-6Synonyms: SCH900353 (Standard)
-
SKL2001 (Standard)
0 ImagesSKL2001 (Standard) is the analytical standard of SKL2001 (HY-101085). This product is intended for research and analytical applications. SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction.
-
NRX-252262 (Standard)
0 ImagesCat. No.: HY-111760RCAS No.: 2438637-61-5NRX-252262 (Standard) is the analytical standard of NRX-252262 (HY-111760). This product is intended for research and analytical applications. NRX-252262 is a potent enhancer of the interaction between β-Catenin, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM.
-
EMT inhibitor-1 (Standard)
0 ImagesCat. No.: HY-101275RCAS No.: 1638526-21-2EMT inhibitor-1 (Standard) is the analytical standard of EMT inhibitor-1 (HY-101275). This product is intended for research and analytical applications. EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities.
-
Laduviglusib trihydrochloride (Standard)
0 ImagesSynonyms: CHIR-99021 trihydrochloride (Standard); CT99021 trihydrochloride (Standard)Laduviglusib (trihydrochloride) (Standard) is the analytical standard of Laduviglusib (trihydrochloride). This product is intended for research and analytical applications. Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib trihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib trihydrochloride induces autophagy.
-
JAK3-IN-7
0 ImagesCat. No.: HY-U00390CAS No.: 1263774-57-7JAK3-IN-7 is a potent and selective JAK3 inhibitor extracted from patent WO2011013785A1, has an IC50 of <0.01 μM.
